MRM MEDIROM Healthcare Technologies Forecast, Technical & Fundamental Analysis

MRM's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for MRM turned positive on September 26, 2025. Looking at past instances where MRM's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Momentum Indicator moved above the 0 level on September 26, 2025. You may want to consider a long position or call options on MRM as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

MRM moved above its 50-day moving average on September 26, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where MRM advanced for three days, in of 176 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MRM broke above its upper Bollinger Band on September 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MRM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.702) is normal, around the industry mean (9.273). P/E Ratio (15.335) is within average values for comparable stocks, (21.181). MRM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.579). MRM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.040). P/S Ratio (0.308) is also within normal values, averaging (636.275).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.